The patients most likely to die from a drug-resistant bacterial infection are, systematically, the patients least represented in the trials used to approve the drugs meant to treat them. That’s the core finding of a new analysis published in Frontiers in Cellular and Infection Microbiology, examining how confidently clinicians can apply newer antibiotics to immunocompromised patients, including cancer patients, transplant recipients, and those on cell-based therapies.
Researchers from China-Japan Union Hospital mapped the evidence behind newer antibiotics authorized in the US or EU between 2014 and 2025, drugs like ceftazidime-avibactam, cefiderocol, and aztreonam-avibactam, developed specifically to fight increasingly lethal resistant pathogens. The stakes are high: bacterial resistance was linked to nearly 4.71 million deaths globally in 2021, and carbapenem-resistant organisms, the specific target of these drugs, accounted for roughly 216,000 of those deaths. Among cancer patients undergoing treatment, resistance rates in bloodstream infections reach 26 to 38 percent for common pathogens.
Despite that, when researchers examined 27 pivotal trials underlying drug approvals, 56 percent explicitly excluded at least one major immunocompromised group, and not a single trial reported outcomes broken down by specific immune status. That matters because immunocompromise isn’t one condition: a chemotherapy patient with severe neutropenia, a transplant recipient on stable immunosuppression, and a child with an inborn immune disorder face entirely different infection risks and drug responses, yet trials that exclude most of them leave clinicians extrapolating blindly.
Real-world data fills some gaps. Cancer and transplant patients have the most post-approval evidence: one study found 30-day mortality of 17.7 percent among blood cancer patients treated with ceftazidime-avibactam, another found 22.2 percent among kidney transplant recipients. But for patients on CAR-T cell therapy, those with advanced HIV, primary immunodeficiencies, or immunocompromised children, the researchers found no phenotype-specific outcome data at all.
The problem compounds in practice. Critically ill immunocompromised patients often have unpredictable drug levels due to kidney injury, dialysis, or rapidly shifting organ function, yet only 8 percent of US health systems surveyed actually monitor beta-lactam drug concentrations in these patients, and a major trial testing concentration-guided dosing found no clear benefit anyway.
The authors frame this as a research-infrastructure problem rather than a flaw in any single drug or company: trials are designed to produce clean, interpretable results, which structurally pushes out exactly the complex patients who need the drugs most. Their proposed fix is prospective, multicenter trials spanning oncology, transplant medicine, HIV care, and critical care, with immune status built into the study design from the start rather than treated as an afterthought.
Sources and further reading
Sun Y, Guo Y, Cui H, Jiang Y, Yu Q. Newer antibiotics for drug-resistant Gram-negative infections in immunocompromised hosts: from pivotal trials to high-risk practice. Frontiers in Cellular and Infection Microbiology. 1 September 2026.
This article was researched and sourced by Global Biodefense editors and reported with Claude AI assistance for drafting and editing.